Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens

Cancer Medicine

Volumn 5, Issue 4, 2016, Pages 607-616

  Ali, Raafi ^a   Baracos, Vickie E ^a   Sawyer, Michael B ^a   Bianchi, Laurent ^b   Roberts, Sarah ^a   Assenat, Eric ^c   Mollevi, Caroline ^b   Senesse, Pierre ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CENTRE VAL D AURELLE   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Body composition; Chemotherapy toxicity; Colon cancer; Irinotecan; Lean body mass; Neuropathy; Oxaliplatin

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADJUVANT THERAPY; ADULT; ADVERSE DRUG REACTION; ANEMIA; ANOREXIA; ARTICLE; CANADA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; FRANCE; HUMAN; HUMAN TISSUE; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MUSCLE TISSUE; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; SIDE EFFECT; AGED; BODY COMPOSITION; BODY MASS; BODY SURFACE; COHORT ANALYSIS; COLONIC NEOPLASMS; COMPLICATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEALTH SURVEY; MIDDLE AGED; NERVOUS SYSTEM DISEASES;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY COMPOSITION; BODY MASS INDEX; BODY SURFACE AREA; CANADA; COHORT STUDIES; COLONIC NEOPLASMS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FLUOROURACIL; FRANCE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; ORGANOPLATINUM COMPOUNDS; POPULATION SURVEILLANCE;

EID: 85006217624     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.621     Document Type: Article

References (37)

1. Sawyer, M., and M. J. Ratain . 2001. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest. New Drugs 19:171-177.
2. Morgan, D. J., and K. M. Bray . 1994. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin. Pharmacokinet. 26:292-307.
3. Aslani, A., R. C. Smith, B. J. Allen, N. Pavlakis, and J. A. Levi . 2000. The predictive value of body protein for chemotherapy-induced toxicity. Cancer 88:796-803.
4. Ratain, M. J. 1998. Body surface area as a basis for dosing of anticancer agents: science, myth or habit? J. Clin. Oncol. 16:2297-2298.
5. Baker, S. D., L. B. Grochow, and R. C. Donehower . 1995. Should anticancer drug doses be adjusted in the obese patient? J. Natl Cancer Inst. 87:333-334.
6. Gusella, M., S. Toso, E. Ferrazzi, M. Ferrari, and R. Padrini . 2002. Relationships between body composition parameters and fluorouracil pharmacokinetics. Br. J. Clin. Pharmacol. 54:131-139.
7. Santini, F., A. Pinchera, A. Marsili, G. Ceccarini, M. G. Coastagna, R. Valeriano, et al. 2005. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J. Clin. Endocrinol. Metab. 90:124-127.
8. Gurney, H. P., S. Ackland, V. Gebski, and G. Farrell . 1998. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J. Clin. Oncol. 16:2299-2304.
9. Roubenoff, R., and J. J. Kehayias . 1991. The meaning and measurement of lean body mass. Nutr. Rev. 49:163-175.
10. Prado, C. M., J. R. Lieffers, L. J. McCargar, T. Reiman, M. B. Sawyer, L. Martin, et al. 2008. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 9:629-635.
11. Martin, L., L. Birdsell, N. Macdonald, T. Reiman, M. T. Clandinin, L. J. McCargar, et al. 2013. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31:1539-1547.
12. Prado, C. M., V. E. Baracos, L. J. McCargar, M. Mourtzakis, K. E. Mulder, T. Reiman, et al. 2007. Body composition as an independent determinant of 5-Fluorouracil-based chemotherapy toxicity. Clin. Cancer Res. 13:3264-3268.
13. Sjøblom, B., B. H. Grønberg, J. Š. Benth, V. E. Baracos, Ø. Fløtten, M. J. Hjermstad, et al. 2015. Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer. Lung Cancer 90:85-91.
14. Kazemi-Bajestani, S. M., V. C. Mazurak, and V. Baracos . 2015. Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes. Semin. Cell Dev. Biol. pii: S1084-9521(15)00160-3. In press.
15. Arrieta, O., M. De la Torre-Vallejo, D. López-Macías, D. Orta, J. Turcott, E. O. Macedo-Pérez, et al. 2015. Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer. Oncologist. 20:967-974.
16. Tan, B. H. L., K. Brammer, N. Randhawa, N. T. Welch, S. L. Parsons, E. J. James, et al. 2015. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur. J. Surg. Oncol. 41:333-338.
17. Prado, C. M., V. E. Baracos, L. J. McCargar, T. Reiman, M. Mourtzakis, K. Tonkin, et al. 2009a. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin. Cancer Res. 15:2920-2926.
18. Ychou, M., M. Rivoire, S. Thezenas, F. Quenet, J. R. Delpero, C. Rebischung, et al. 2013. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Ann. Surg. Oncol. 20:4289-4297.
19. Assenat, E., F. Desseigne, S. Thezenas, F. Viret, L. Mineur, A. Kramar, et al. 2011. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist 16:1557-1564.
20. Heymsfield, S. B., Z. Wang, R. N. Baumgartner, and R. Ross . 1997. Human body composition: advances in models and methods. Annu. Rev. Nutr. 17:527-558.
21. Prado, C. M., L. A. Birdsell, and V. E. Baracos . 2009b. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 3:269-275.
22. Mitsiopoulos, N., R. N. Baumgartner, S. B. Heymsfield, W. Lyons, D. Gallagher, and R. Ross . 1998. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J. Appl. Physiol. 85:115-122.
23. Mourtzakis, M., C. M. Prado, J. R. Lieffers, T. Reiman, L. J. McCargar, and V. E. Baracos . 2008. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl. Physiol. Nutr. Metab. 33:997-1006.
24. Antoun, S., V. E. Baracos, L. Birdsell, B. Escudier, and M. B. Sawyer . 2010. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann. Oncol. 21:1594-1598.
25. Shen, W., M. Punyanitya, Z. Wang, D. Gallagher, M. P. St-Onge, J. Albu, et al. 2004. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J. Appl. Physiol. 97:2333-2338.
26. Williams, B. A., J. A. Mandrekar, S. J. Mandrekar, et al. 2006. Finding optimal cutpoints for continuous covariates with binary and time-to-event outcomes. Rochester MN, Mayo Foundation. Technical Report Series 79.
27. Wong, A. L., K. Y. Seng, E. M. Ong, L. Z. Wang, H. Oscar, M. T. Cordero, et al. 2014. Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. Breast Cancer Res. Treat. 144:143-152.
28. Cousin, S., A. Hollebecque, S. Koscielny, O. Mir, A. Varga, V. E. Baracos, et al. 2013. Low skeletal muscle is associated with toxicity in patients included in phase I trials. Invest. New Drugs 32:382-387.
29. Barrat, M., S. Antoun, D. Malka, T. Mansourbakht, A. Zaanan, E. Latko, et al. 2014. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr. Cancer 66:583-589.
30. Schmoll, H. J., T. Buchele, A. Grothey, and W. Dempke . 1999. Where do we stand with 5- fluorouracil? Semin. Oncol. 26:589-605.
31. Sloan, J. A., R. M. Goldberg, D. J. Sargent, D. Vargas-Chanes, S. Nair, S. S. Cha, et al. 2002. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J. Clin. Oncol. 20:1491-1498.
32. Milano, G., M. C. Etienne, V. Pierrefite, M. Barberi-Heyob, R. Deport-Fety, and N. Renée . 1999. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br. J. Cancer 79:627-630.
33. Sloan, J. A., C. L. Loprinzi, P. J. Novotny, S. Okuno, S. Nair, and D. L. Barton . 2000. Sex differences in fluorouracil-induced stomatitis. J. Clin. Oncol. 18:412-420.
34. Etienne, M. C., J. L. Lagrange, O. Dassonville, R. Fleming, A. Thyss, N. Renee, et al. 1994. Population study of Dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol. 12:2248-2253.
35. Port, R. E., B. Daniel, B. Daniel, R. W. Ding, and R. Herrmann . 1991. Relative importance of dose, body surface area, sex and age for 5-fluorouracil clearance. Oncology 48:277-281.
36. Milano, G., M. C. Etienne, E. Cassuto-Viguier, A. Thyss, J. Santini, M. Frenay, et al. 1992. Influence of sex and age on fluorouracil clearance. J. Clin. Oncol. 10:1171-1175.
37. Pietrobelli, A., Z. Wang, and S. B. Heymsfield . 1998. Techniques used in measuring human body composition. Curr. Opin. Clin. Nutr. Metab. Care 1:439-448.